Anthony Schwarer

Professor

19952019
If you made any changes in Pure these will be visible here soon.

Research Output 1995 2019

Filter
Meeting Abstract
2018

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study: Blood 2018 132:459

Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowlings, P., Reynolds, J., Cushion, R., Harrup, R., Ross, D. M., Kipp, D., Mills, A. K., Arthur, C., Schwarer, A. P., Jackson, K., Viiala, N., Weinkove, R., Yong, A., White, D. L., Branford, S. & 1 others, Hughes, T. P., Nov 2018, In : Blood. 132, Suppl 1, p. 459-459 1 p.

Research output: Contribution to journalMeeting AbstractOtherpeer-review

2017

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study: Blood 2017 130:2898

Yeung, D., Grigg, A., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., Reynolds, J., Cushion, R., Harrap, R., Ross, D. M., Kipp, D., Mills, A. K., Arthur, C. K., Schwarer, A. P., Jackson, K., Viiala, N., Weinkove, R., Yong, A. S. M., White, D. L., Branford, S. & 1 others, Hughes, T. P., 7 Dec 2017, In : Blood. 130, Suppl 1, 2898.

Research output: Contribution to journalMeeting AbstractOtherpeer-review

2011

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Hughes, T. P., Lipton, J. H., Leber, B., Spector, N., Cervantes, F., Pasquini, R., Clementino, N., Schwarer, A. P., Mahon, F-X., Rea, D., Yeung, D. T., Kamel-Reid, S., Bendit, I., Reynolds, J., Williams, L., Szczudlo, T. & Branford, S., 18 Nov 2011, In : Blood. 118, 21, 606.

Research output: Contribution to journalMeeting AbstractOtherpeer-review